
Multiplex immunofluorescence · QuPath
Multiplex immunofluorescence as a clinical-trial endpoint
Frontiers in Immunology, 2025
- Challenge
- A pilot clinical trial of neoadjuvant imiquimod, a Toll-like receptor 7 agonist, in early-stage oral cancer needed a quantitative, tissue-based primary endpoint.
- Approach
- Pre- and post-treatment biopsies were analyzed in QuPath: StarDist cell segmentation, marker-based classification of tumour and immune populations, tumour cell counts, and spatial metrics of immune-cell proximity to tumour cells.
- Outcome
- The analysis quantified treatment response and showed significant increases in cytotoxic and helper T cells after treatment, profiling how the tumour microenvironment changed.



